Skip to content

Author

Ankush Kumar

We have 6 of 21 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Recent advances in scaffold-based KRASG12C inhibitors: SAR and biological evaluation insights.

Over the past decade, targeting Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations has shifted from being considered an undruggable target to becoming a realistic therapeutic strategy with the development of KRASG12C inhibitors. This mutation replaces glycine with cysteine at codon 12, thereby reducing the GTP...

Tomojit Bhattacharjee, Ankush Kumar, Thakur Gurjeet Singh et al. · 0 citations
Open access Sep 2026

Design, Synthesis, Molecular Dynamics, and In Vitro Evaluation of Isatin‐Based Quinazoline Derivatives as Potential Antidiabetic Agents

SJ2 is a promising lead for α‐amylase inhibition, which needs further optimization and biological validation, and future evaluation against α‐glucosidase and relevant in vivo models will be essential to determine the more general antidiabetic potential of this scaffold.

Sahil Jaidka, Ankush Kumar, Christopher Basumatary et al. · 0 citations
Review Sep 2026

Artificial Intelligence-Driven Strategies for Predicting, Personalizing, and Optimizing Therapeutic Targets in Inflammatory Bowel Disease.

Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, represent chronic relapsing inflammatory disorders characterized by complex interactions among genetic, microbiome-related, immunological, and environmental factors. Although advances in biologics and small-molecule inhibitors have exp...

Priyanka Paul, Ankush Kumar, Rajwinder Kaur et al. · 0 citations
Review Sep 2026

Neolignans as emerging anticancer leads: Isolation, chemical diversity, structure-activity relationships.

Neolignans are potential natural product-derived anticancer leads; rational SAR-guided optimization, sophisticated delivery methods, and computational drug development may speed up their clinical translation.

Samarth Kumar, Ankush Kumar, Thakur Gurjeet Singh et al. · 0 citations
Review Open access Aug 2026

Pyridopyrimidines and Pyridopyrimidinones as Kinase-Targeted Anticancer Agents: Medicinal Chemistry and Mechanistic Insights

Overall, pyridopyrimidine- and pyridopyrimidinones-based compounds continue to show great promise as potential anticancer agents and further research combining synthetic chemistry, biological studies, and computational approaches may lead to the development of more effective and safer drugs in the future.

Ankush Kumar, Rajwinder Kaur, Bhupinder Kumar et al. · 0 citations
Review Jul 2026

Nanocarrier-based targeting strategies in epilepsy: addressing pathophysiological barriers.

Nanomedicine represents a promising approach for overcoming the limitations of conventional epilepsy therapy by enabling efficient brain-targeted drug delivery by enabling efficient brain targeting of antiepileptic drugs.

Abhishek Chauhan, Ankush Kumar, Ankit Awasthi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.